Northern Trust Corp Akero Therapeutics, Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 620,321 shares of AKRO stock, worth $27.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

620,321

Previous 584,584 6.11%

Holding current value

$27.8 Million

Previous $16.8 Million 2.9%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$26.75 - $35.28 $955,964 - $1.26 Million	35,737 Added 6.11%	620,321 $17.3 Million
Q3 2024 Nov 13, 2024	SELL	$21.45 - $29.34 $70,398 - $96,293	-3,282 Reduced 0.56%	584,584 $16.8 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $179,840 - $241,817	-9,822 Reduced 1.64%	587,866 $13.8 Million
Q1 2024 May 14, 2024	BUY	$17.76 - $31.18 $1.01 Million - $1.78 Million	57,003 Added 10.54%	597,688 $15.1 Million
Q4 2023 Feb 13, 2024	BUY	$11.38 - $50.33 $30,293 - $133,978	2,662 Added 0.49%	540,685 $12.6 Million
Q3 2023 Nov 13, 2023	BUY	$41.19 - $52.25 $3.2 Million - $4.05 Million	77,594 Added 16.85%	538,023 $27.2 Million
Q2 2023 Aug 11, 2023	BUY	$36.89 - $56.88 $3.79 Million - $5.84 Million	102,662 Added 28.7%	460,429 $21.5 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $93,547 - $126,102	-2,510 Reduced 0.7%	357,767 $13.7 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $3.2 Million - $5.25 Million	95,767 Added 36.21%	360,277 $19.7 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $205,354 - $688,899	20,232 Added 8.28%	264,510 $9.01 Million
Q2 2022 Aug 12, 2022	BUY	$8.0 - $15.01 $66,824 - $125,378	8,353 Added 3.54%	244,278 $2.31 Million
Q1 2022 May 13, 2022	SELL	$12.97 - $22.26 $179,621 - $308,278	-13,849 Reduced 5.54%	235,925 $3.35 Million
Q4 2021 Feb 08, 2022	BUY	$19.87 - $26.24 $56,251 - $74,285	2,831 Added 1.15%	249,774 $5.28 Million
Q3 2021 Nov 15, 2021	SELL	$18.65 - $25.46 $187,786 - $256,356	-10,069 Reduced 3.92%	246,943 $5.52 Million
Q2 2021 Aug 13, 2021	BUY	$24.81 - $32.35 $2.06 Million - $2.69 Million	83,012 Added 47.71%	257,012 $6.38 Million
Q1 2021 May 12, 2021	SELL	$24.04 - $34.19 $311,750 - $443,375	-12,968 Reduced 6.94%	174,000 $5.05 Million
Q4 2020 Feb 11, 2021	SELL	$25.12 - $29.89 $128,513 - $152,917	-5,116 Reduced 2.66%	186,968 $4.82 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $1.17 Million - $1.52 Million	38,032 Added 24.69%	192,084 $5.91 Million
Q2 2020 Aug 14, 2020	BUY	$19.25 - $26.76 $1.04 Million - $1.45 Million	54,190 Added 54.26%	154,052 $3.84 Million
Q1 2020 May 14, 2020	BUY	$12.8 - $27.05 $392,972 - $830,462	30,701 Added 44.39%	99,862 $2.12 Million
Q4 2019 Feb 14, 2020	SELL	$17.37 - $27.27 $13,461 - $21,134	-775 Reduced 1.11%	69,161 $1.54 Million
Q3 2019 Nov 13, 2019	BUY	$16.89 - $29.88 $989,889 - $1.75 Million	58,608 Added 517.37%	69,936 $1.59 Million
Q2 2019 Aug 13, 2019	BUY	$18.08 - $19.83 $204,810 - $224,634	11,328 New	11,328 $217,000

Others Institutions Holding AKRO

# of Institutions

210

Shares Held

74.3M

Call Options Held

321K

Put Options Held

558K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.08B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Akero Therapeutics, Inc. Transaction History